Beyond Osimertinib: The Development of Third-Generation EGFR TKIs
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Journal of Thoracic Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Beyond Osimertinib: The Development of 3rd-Generation EGFR Tyrosine Kinase Inhibitors
J Thorac Oncol 2020 Dec 15;[EPub Ahead of Print], M Nagasaka, VW Zhu, SM Lim, M Greco, F Wu, SH Ignatius OuFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.